Literature DB >> 10202013

An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest.

C L Sutherland1, D L Krebs, M R Gold.   

Abstract

We have previously shown that CD40 causes strong activation of the c-Jun N-terminal kinase (JNK), the p38 mitogen-activated protein kinases (MAPK) and MAPKAP kinase-2, a downstream target of p38 MAPK. To identify signaling motifs in the CD40 cytoplasmic domain that are responsible for activation of these kinases, we have created a set of 11 chimeric receptors consisting of the extracellular and transmembrane domains of CD8 fused to portions of the murine CD40 cytoplasmic domain. These chimeric receptors were expressed in WEHI-231 B lymphoma cells. We found that amino acids 35-45 of the CD40 cytoplasmic domain constitute an independent signaling motif that is sufficient for activation of the JNK and p38 MAPK pathways, as well as for induction of I kappa B alpha phosphorylation and degradation. Amino acids 35-45 were also sufficient to protect WEHI-231 cells from anti-IgM-induced growth arrest. This is the same region of CD40 required for binding the TNF receptor-associated factor-2 (TRAF2), TRAF3, and TRAF5 adapter proteins. These data support the idea that one or more of these TRAF proteins couple CD40 to the kinase cascades that activate NF-kappa B, JNK, and p38 MAPK.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202013

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

2.  The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation.

Authors:  Li-Fan Lu; Cory L Ahonen; Evan F Lind; Vanitha S Raman; W James Cook; Ling-Li Lin; Randolph J Noelle
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

3.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis.

Authors:  Peter Ellmark; Christina Furebring; Carl A K Borrebaeck
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

5.  A cell-penetrating CD40-TRAF2,3 blocking peptide diminishes inflammation and neuronal loss after ischemia/reperfusion.

Authors:  Jose-Andres C Portillo; Jin-Sang Yu; Samuel Hansen; Timothy S Kern; M Cecilia Subauste; Carlos S Subauste
Journal:  FASEB J       Date:  2021-03       Impact factor: 5.191

6.  Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation.

Authors:  U D Bajpai; K Zhang; M Teutsch; R Sen; H H Wortis
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

Review 7.  Glycosylation in lymphoma: Biology and glycotherapy.

Authors:  Osamu Suzuki
Journal:  Pathol Int       Date:  2019-07-17       Impact factor: 2.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.